MX348860B - Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. - Google Patents

Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.

Info

Publication number
MX348860B
MX348860B MX2013012313A MX2013012313A MX348860B MX 348860 B MX348860 B MX 348860B MX 2013012313 A MX2013012313 A MX 2013012313A MX 2013012313 A MX2013012313 A MX 2013012313A MX 348860 B MX348860 B MX 348860B
Authority
MX
Mexico
Prior art keywords
acetyl
coa carboxylase
pyrazolospiroketone
derivatives
carboxylase inhibitors
Prior art date
Application number
MX2013012313A
Other languages
English (en)
Other versions
MX2013012313A (es
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013012313A publication Critical patent/MX2013012313A/es
Publication of MX348860B publication Critical patent/MX348860B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un compuesto de Fórmula (I) (Ver Formula) o una sal del mismo aceptable desde el punto de vista farmacéutico; donde G es (Ver Formulas) R1, R2 y R3 son como se describe en la presente; composiciones farmacéuticas del mismo; y el uso del mismo en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una enzima(s) acetil-.CoA carboxilasa en un animal.
MX2013012313A 2011-04-22 2012-04-09 Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. MX348860B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (en) 2011-04-22 2012-04-09 Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors

Publications (2)

Publication Number Publication Date
MX2013012313A MX2013012313A (es) 2014-01-31
MX348860B true MX348860B (es) 2017-06-30

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012313A MX348860B (es) 2011-04-22 2012-04-09 Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.

Country Status (42)

Country Link
US (4) US8802688B2 (es)
EP (1) EP2699576B1 (es)
JP (1) JP5657174B2 (es)
KR (1) KR101567659B1 (es)
CN (2) CN106117205B (es)
AP (1) AP3499A (es)
AR (1) AR086198A1 (es)
AU (1) AU2012245996B2 (es)
CA (1) CA2831380C (es)
CL (1) CL2013002794A1 (es)
CO (1) CO6801757A2 (es)
CR (1) CR20130464A (es)
CU (1) CU24164B1 (es)
CY (1) CY1117122T1 (es)
DK (1) DK2699576T3 (es)
DO (1) DOP2013000243A (es)
EA (1) EA022375B1 (es)
EC (1) ECSP13013038A (es)
ES (1) ES2561452T3 (es)
GE (1) GEP20166474B (es)
GT (1) GT201300258A (es)
HR (1) HRP20151397T1 (es)
HU (1) HUE028602T2 (es)
IL (1) IL228949A (es)
MA (1) MA35061B1 (es)
ME (1) ME02312B (es)
MX (1) MX348860B (es)
MY (1) MY162167A (es)
NI (1) NI201300111A (es)
NZ (1) NZ616156A (es)
PE (1) PE20141187A1 (es)
PH (1) PH12013501941A1 (es)
PL (1) PL2699576T3 (es)
PT (1) PT2699576E (es)
RS (1) RS54526B1 (es)
SG (1) SG194142A1 (es)
SI (1) SI2699576T1 (es)
TN (1) TN2013000393A1 (es)
TW (1) TWI464171B (es)
UA (1) UA107753C2 (es)
UY (1) UY34027A (es)
WO (1) WO2012143813A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2778886C (en) * 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法
EP2970104B1 (en) 2013-03-14 2019-04-24 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
JP6417403B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
EP2994138A4 (en) * 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
EP2994139B1 (en) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
BR112016004118A2 (pt) * 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
WO2015056782A1 (ja) 2013-10-17 2015-04-23 塩野義製薬株式会社 新規アルキレン誘導体
CN108947867A (zh) * 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
CN113336653A (zh) * 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
US10457502B2 (en) 2014-05-22 2019-10-29 Symbotic Canada Ulc Tool and method for layer depalletizing
EP3193855B1 (en) 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
WO2017114413A1 (zh) * 2015-12-31 2017-07-06 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
HUE061885T2 (hu) 2017-11-21 2023-08-28 Pfizer 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN120457124A (zh) * 2022-12-30 2025-08-08 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−4受容体作動薬としてのアシル化ピペリジン誘導体
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
ES2327857T3 (es) 2004-05-12 2009-11-04 Pfizer Products Inc. Derivados de prolina y su uso como inhibidores de la dipeptidil peptidasa iv.
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
BRPI0510273A (pt) 2004-05-25 2007-10-30 Pfizer Prod Inc derivados de tetraazabenzo[e]azuleno e análogos destes
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US7410976B2 (en) 2005-07-19 2008-08-12 Merck & Co., Inc. Spirochromanone derivatives
EP1911753A1 (en) 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
EP1951251B1 (en) 2005-11-18 2010-12-29 Merck Sharp & Dohme Corp. Spirohydantoin aryl cgrp receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
EP2097420B1 (en) 2006-11-29 2012-04-04 Pfizer Products Inc. Spiroketone inhibitors of acetyl-coa carboxylase
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) * 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な3−アミド−ピロロ[3,4−c]ピラゾール−5(1H,4H,6H)カルバルデヒド誘導体
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2297163B1 (en) * 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2010002010A1 (en) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
US8110570B2 (en) 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
WO2010013161A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ATE540040T1 (de) 2008-08-28 2012-01-15 Pfizer Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CA2778316A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2778886C (en) 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) * 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase

Also Published As

Publication number Publication date
MX2013012313A (es) 2014-01-31
MA35061B1 (fr) 2014-04-03
NZ616156A (en) 2014-08-29
PE20141187A1 (es) 2014-09-18
ES2561452T3 (es) 2016-02-26
TW201305162A (zh) 2013-02-01
US20120270893A1 (en) 2012-10-25
ME02312B (me) 2016-06-20
DK2699576T3 (en) 2016-02-15
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
CN106117205B (zh) 2018-09-21
US8802688B2 (en) 2014-08-12
AU2012245996A1 (en) 2013-10-03
IL228949A0 (en) 2013-12-31
SG194142A1 (en) 2013-11-29
TWI464171B (zh) 2014-12-11
AR086198A1 (es) 2013-11-27
ECSP13013038A (es) 2014-01-31
SI2699576T1 (sl) 2016-02-29
PL2699576T3 (pl) 2016-05-31
AU2012245996B2 (en) 2016-09-01
PT2699576E (pt) 2016-03-09
CL2013002794A1 (es) 2013-12-27
CA2831380A1 (en) 2012-10-26
IL228949A (en) 2016-11-30
KR20140015511A (ko) 2014-02-06
CN106117205A (zh) 2016-11-16
UA107753C2 (xx) 2015-02-10
CR20130464A (es) 2013-10-16
DOP2013000243A (es) 2013-12-31
US20150336958A1 (en) 2015-11-26
HUE028602T2 (hu) 2016-12-28
CO6801757A2 (es) 2013-11-29
MY162167A (en) 2017-05-31
GEP20166474B (en) 2016-05-10
RS54526B1 (sr) 2016-06-30
CA2831380C (en) 2016-04-05
EP2699576A1 (en) 2014-02-26
EP2699576B1 (en) 2015-12-09
AP2013007129A0 (en) 2013-09-30
AP3499A (en) 2015-12-31
HRP20151397T1 (hr) 2016-01-15
EA022375B1 (ru) 2015-12-30
GT201300258A (es) 2015-06-02
KR101567659B1 (ko) 2015-11-09
JP2014515755A (ja) 2014-07-03
EA201391288A1 (ru) 2014-04-30
PH12013501941A1 (en) 2021-06-23
WO2012143813A1 (en) 2012-10-26
JP5657174B2 (ja) 2015-01-21
UY34027A (es) 2013-04-05
CU24164B1 (es) 2016-03-31
US20150112068A1 (en) 2015-04-23
TN2013000393A1 (fr) 2015-01-20
CY1117122T1 (el) 2017-04-05
CU20130126A7 (es) 2014-01-29
CN103492388A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
PH12013501941A1 (en) Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
MY172924A (en) Neprilysin inhibitors
HK1213251A1 (zh) 作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物
UA109614C2 (uk) ПОХІДНІ ТІЄНО[3,2-d]ПІРИМІДИНУ, ЩО МАЮТЬ ІНГІБУЮЧУ АКТИВНІСТЬ ВІДНОСНО ПРОТЕЇНКІНАЗ
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
PH12014501215A1 (en) Peptide deformylase inhibitors
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors

Legal Events

Date Code Title Description
FG Grant or registration